PTO Grants Reissued Patent Replacing OSI Pharma’s Tarceva Patent

OSI Pharmaceuticals, Inc. Tuesday announced that the U.S. Patent & Trademark Office has granted reissue patent RE41,065, replacing Tarceva’s (erlotinib) composition of matter patent.
StreetInsider